Effect of Arohana Anuvasana Vasti with Prabhanjanavimardanam Taila in Lumbar Spondylosis

Abstract

Lumbar spondylosis is a chronic, non-inflammatory condition characterised by deterioration of the lumbar spine's discs, vertebral bodies, and facet joints. Lumbar spondylosis can be associated with Kateegraha, described in our classics. Lumbar spondylosis is a Dhatukshayajanya vatavikara, and Vasti being the prime treatment modality for Vata, the present effort is to study the effect of Prabhanjanavimardanam taila, mentioned in the Tailaprakarana of Sahasrayoga, which is indicated for Ashiti vatarogas in as Pana, Abhyanga, Nasya, and Vastikarma, and hence is a good choice in this condition. Considering both the Dosa kopa and the vitiated Dosa sthana, anuvasana was selected as the mode of administration. Materials and Methods: The study design is an experimental study with a pre-post assessment without a control group. Participants, irrespective of sex, aged between 30-60 years, registered in the OPD and IPD of Government Ayurveda Panchakarma Hospital, Poojappura, Thiruvananthapuram, diagnosed to have lumbar spondylosis and satisfying the inclusion criteria, were selected. The baseline data was gathered by interviews, observations, and questionnaires. A total of 25 people were chosen for the study. The participants were given Deepana pachana medicines for 3 days, followed by the administration of Arohana anuvasana vasti with Prabhanjanavimardanam taila for 9 consecutive days at a fixed escalating dose. The participants were assessed before and after with regard to changes in subjective parameters like pain, tenderness, and morning stiffness measured by VAS score, Quebec Back Pain Disability Scale, and range of movements by goniometry. Results and discussion: Data were statistically analysed using the Wilcoxon signed-rank test and the paired t-test. In all these parameters, significant reductions in symptoms were noted. Conclusion: The study concludes that Arohana anuvasana vasti with Prabhanjanavimardanam taila is effective in reducing signs and symptoms of participants with lumbar spondylosis. (CTRI/2024/07/071523).